Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of “Hold” by Analysts

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have been assigned a consensus rating of “Hold” from the nine research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $27.22.

PCRX has been the topic of a number of recent analyst reports. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. HC Wainwright increased their target price on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Barclays upped their price target on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. Finally, Needham & Company LLC increased their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 28th.

Institutional Trading of Pacira BioSciences

Large investors have recently bought and sold shares of the company. Sterling Capital Management LLC lifted its position in shares of Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after purchasing an additional 1,208 shares in the last quarter. Ancora Advisors LLC acquired a new position in Pacira BioSciences in the 4th quarter worth $26,000. Caitlin John LLC boosted its position in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after buying an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after acquiring an additional 2,749 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after acquiring an additional 513 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Trading Down 2.4 %

Shares of PCRX stock opened at $24.29 on Friday. The firm’s 50-day simple moving average is $24.91 and its 200-day simple moving average is $20.23. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $31.67. The firm has a market cap of $1.12 billion, a P/E ratio of -11.97 and a beta of 0.70.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.